78
Participants
Start Date
September 1, 2022
Primary Completion Date
April 18, 2024
Study Completion Date
June 13, 2024
Visit 1: Clinical exam and questionnaires
Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
Visit 1: Respiratory physiology
FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
Visit 1: Inflammometry
Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
Visit 2: Clinical exam and questionnaires
Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
Visit 2: Respiratory physiology
FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
Visit 2: Inflammometry
SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
Visit 3: e-mail
ACQ-5, peak flow measurement, and questions about the patient's asthma management.
Centre de Recherche du CHUS, Sherbrooke
Collaborators (1)
Sanofi-Regeneron
UNKNOWN
Réseau de Recherche en Santé Respiratoire du Québec
UNKNOWN
Association Pulmonaire du Quebec
OTHER
BioMérieux
INDUSTRY
Fonds de la Recherche en Santé du Québec
OTHER_GOV
Université de Sherbrooke
OTHER